Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Vir Biotechnology's annualizedNet Income for the quarter that ended in Jun. 2026 was MXN5,589 Mil. Vir Biotechnology's average total tangible assets for the quarter that ended in Jun. 2026 was MXN19,408 Mil. Therefore, Vir Biotechnology's annualized Return-on-Tangible-Asset for the quarter that ended in Jun. 2026 was 28.80%.
The historical rank and industry rank for Vir Biotechnology's Return-on-Tangible-Asset or its related term are showing as below:
MEX:VIR'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -68.88 Med: -35.15 Max: 38.14
Current: -23.6
During the past 9 years, Vir Biotechnology's highest Return-on-Tangible-Asset was 38.14%. The lowest was -68.88%. And the median was -35.15%.
MEX:VIR's Return-on-Tangible-Asset is ranked better than 60% of 1415
companies
in the Biotechnology industry
Industry Median: -36.15
vs MEX:VIR: -23.60
Vir Biotechnology (MEX:VIR) Return-on-Tangible-Asset Explanation
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Vir Biotechnology Return-on-Tangible-Asset Related Terms
Vir Biotechnology Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Vir Biotechnology's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:VIR vs AVBP, XNCR, SEPN: Return-on-Tangible-Asset Comparison
For the Biotechnology subindustry, Vir Biotechnology's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vir Biotechnology Return-on-Tangible-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Vir Biotechnology's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Vir Biotechnology's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Jun. 2026) net income data.
What does a Return-on-Tangible-Asset of 28.80% mean?
Vir Biotechnology (MEX:VIR) has a Return-on-Tangible-Asset of 28.80% as of Jun. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Vir Biotechnology and its competitors. According to the industry distribution chart, Vir Biotechnology ranks #566 out of 1415 companies in the Biotechnology industry, placing it in the top 40%.
Is Vir Biotechnology's Return-on-Tangible-Asset too high?
Vir Biotechnology's current Return-on-Tangible-Asset is 28.80%. Based on the distribution chart, Vir Biotechnology ranks #566 out of 1415 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Vir Biotechnology has a GF Score™ of 52/100, reflecting its overall financial health beyond just this single metric.
How does Vir Biotechnology's Return-on-Tangible-Asset compare to AVBP and XNCR?
According to the Biotechnology industry distribution chart, Vir Biotechnology ranks #566 out of 1415 companies for Return-on-Tangible-Asset. This puts Vir Biotechnology in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Biotechnology company?
A good Return-on-Tangible-Asset depends on the Biotechnology industry context. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Vir Biotechnology and its competitors. Vir Biotechnology's current Return-on-Tangible-Asset is 28.80%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vir Biotechnology stock overvalued right now?
Vir Biotechnology (MEX:VIR) has a current Return-on-Tangible-Asset of 28.80%. The stock's GF Value™ is MXN755.16, compared to a current price of MXN170.00 — trading 77.5% below its estimated fair value. The current Return-on-Tangible-Asset is 28.80%. Vir Biotechnology's overall GF Score™ is 52/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Vir Biotechnology (MEX:VIR), the current Return-on-Tangible-Asset is 28.80% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vir Biotechnology (MEX:VIR) Overvalued in 2026?
Based on GuruFocus' analysis, Vir Biotechnology stock appears to be undervalued.
The current stock price of MXN170.00 is trading 77.5% below its estimated GF Value™ of MXN755.16.
Key valuation signals for MEX:VIR:
Return-on-Tangible-Asset: 28.80%
GF Value™: MXN755.16 vs. price of MXN170.00 (77.5% below fair value)
No single metric tells the full story. See the MEX:VIR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vir Biotechnology Inc is a clinical-stage biopharmaceutical company focused on powering the immune system by discovering and developing medicines for serious infectious diseases and cancer. The company uses its capabilities in antibody discovery and engineering, coupled with its proprietary AI engine dAIsY system, and the PRO-XTEN masking platform, to quickly and effectively discover and optimize potential new medicines. Its clinical development pipeline consists of investigational therapies like Tobevibart + elebsiran targeting the hepatitis delta virus (HDV), preclinical antibody candidates targeting HIV, and VIR-5500, VIR-5818, VIR-5525, and 7 PRO-XTEN programs targeting multiple solid tumors. Currently, the company generates revenue mainly by issuing license rights and through grants.
52GF Score
Get the complete analysis for MEX:VIR
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:VIR has been successfully added to your 
